CURE highlights prostate cancer advancements from Day One of the 2026 ASCO Genitourinary Cancers Symposium.

Overall, day two of ASCO GU emphasized that advances in therapy must go hand-in-hand with patient-centered research. These ...

The presentations at ASCO GU signal a move toward more personalized, potent, and sequence-specific treatment strategies for genitourinary malignancies.

MARCAP investigators conducted the first individual patient data meta-analysis of randomized trials (POSEIDON) evaluating the use and duration hormone therapy with postoperative radiation therapy in ...

The combination of belzutifan plus lenvatinib significantly improved outcomes for patients with clear cell renal cell carcinoma who progressed following immunotherapy compared with cabozantinib ...

Of the phase III trials that planned to report QoL outcomes, nearly 40% never did ...

Dr Parikh explained that KEYNOTE-B15 (NCT04700124) is evaluating the role of perioperative enfortumab vedotin (Padcev), an antibody-drug conjugate, in combination with the immune checkpoint inhibitor ...

When a doctor suspects bladder cancer, they will order a series of tests which may include urine tests (urinalysis or urine ...

Prostate tumors contain more microplastics than healthy prostate tissue, researchers from New York University Langone Health ...

The 2026 GU ASCO annual meeting featured a urothelial carcinoma session and a discussant presentation by Dr. Tyler F. Stewart ...